FundraiseJun 25, 2026, 20:38 UTC

Aiforia Technologies raises ~€6.4M in directed share issue

What's the deal? Finnish medtech firm Aiforia Technologies has raised roughly €6.4 million through a directed share issue to institutional and qualified investors.

The company issued 3,600,000 new shares at €1.772 each — matching its June 25 closing price. That lifts its total share count to 37,386,604.

The new shares represent about 9.6% of issued shares after the placing. Net proceeds will fund Aiforia's growth strategy.

Why now? The raise used an accelerated bookbuilding process, which lets companies tap investors quickly when market conditions are right.

Its board acted on an authorisation, granted at a May 12 extraordinary general meeting, to issue up to 5,000,000 new shares.

Trading in the new shares is expected to start on Nasdaq First North Growth Market Finland on or about June 30. Evli Plc acted as sole bookrunner and financial advisor.

What could go wrong? The placing dilutes existing shareholders, who now own a smaller slice of the company.

Pricing at the closing share price leaves little cushion, so Aiforia must turn the cash into growth fast to justify the issue.

The signal: The accelerated bookbuilding underlines how Aiforia, a breakout-stage company offering AI-powered pathology image analysis software for researchers, is leaning on listed equity rather than venture capital to fund its growth push. With Evli acting as sole bookrunner, the raise reflects steady institutional appetite for AI in healthcare diagnostics, even as the closing-price pricing leaves the company little room to disappoint on execution.